In May 2023, the U.S. Food and Drug Administration (FDA) announced it had granted accelerated approval for the first CD20 bispecific antibody drug, epcoritamab-bysp (Epkinly^™) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). In June 2024, the FDA expanded the indication with accelerated approval for the treatment of relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.